Immunotherapy as first treatment for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have advanced or locally advanced gastric cancer
- You haven't received any previous anti-cancer treatments like chemotherapy or immunotherapy
- You are expected to start immunotherapy as your first or neoadjuvant therapy
- You have a good performance status (able to do daily activities without major help)
- Your organs are working well enough (like liver, kidneys, and bone marrow)
- You do not have a weak immune system or an autoimmune disease (like lupus or rheumatoid arthritis)
- You do not have an active serious infection (like tuberculosis) or need strong antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called rilvegostomig combined with standard chemotherapy to see if it can help people with advanced stomach or gastroesophageal junction cancer. It may boost the body's immune system to fight the cancer better.
This Phase 3 trial tests an “immunotherapy first” approach before surgery for certain stomach (gastric) cancers. The goal is to increase immune cells inside the tumor, which may improve outcomes after surgery.
This trial tests a combination of short-course radiation, standard chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with advanced or metastatic gastric cancer that hasn't spread to lymph nodes. The goal is to see if this approach can help shrink or control the tumor.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.